EP Patent

EP2488165A1 — Nanoparticle of the core-shell type suitable for delivering therapeutic oligonucleotides to target tissues and the use thereof for the preparation of a medicament for treating duchenne muscular dystrophy

Assigned to Universita degli Studi di Ferrara · Expires 2012-08-22 · 14y expired

What this patent protects

A nanoparticle of the core-shell type is described, which is suitable for delivering therapeu¬ tic oligonucleotides into muscle fibres, particularly antisense oligoribonucleotides capable of restoring, in all or in part, the expression of the dystrophin protein by the exon skippi…

USPTO Abstract

A nanoparticle of the core-shell type is described, which is suitable for delivering therapeu¬ tic oligonucleotides into muscle fibres, particularly antisense oligoribonucleotides capable of restoring, in all or in part, the expression of the dystrophin protein by the exon skipping mecha¬ nism, and thus effective in the treatment of Duchenne muscular dystrophy. Moreover, a nanoparti- cle/oligonucleotide complex effective in the treatment of Duchenne muscular dystrophy is de¬ scribed.

Drugs covered by this patent

Patent Metadata

Patent number
EP2488165A1
Jurisdiction
EP
Classification
—
Expires
2012-08-22
Drug substance claim
No
Drug product claim
No
Assignee
Universita degli Studi di Ferrara
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.